CoBIS 2: Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke

Sponsor
Joanne Kurtzberg, MD (Other)
Overall Status
Completed
CT.gov ID
NCT03004976
Collaborator
The Marcus Foundation (Other), Emory University (Other), M.D. Anderson Cancer Center (Other)
83
6
2
48.4
13.8
0.3

Study Details

Study Description

Brief Summary

The primary objective of this study is to determine the efficacy of a single intravenous infusion of unrelated donor umbilical cord blood (UCB) for improving functional outcomes in patients with ischemic stroke. Eligible subjects will receive an intravenous infusion of UCB or placebo 3-10 days following stroke. Subjects will not receive immunosuppressive or myeloablative medications prior to the infusion. Subjects will be followed for one year post infusion for safety and efficacy. Assessments will examine safety and tolerability of the infusion, change in neurological symptoms, change in quality of life, and emotional and cognitive status. Assessments will occur at 24 hours post infusion, and at 30, 90, 180 and 365 days post infusion.

Condition or Disease Intervention/Treatment Phase
  • Biological: Umbilical Cord Blood
  • Other: Placebo
Phase 2

Detailed Description

This is a multicenter, placebo controlled, randomized, double blinded Phase 2 study in 100 subjects 18-90 years of age who have sustained a recent ischemic stroke. Potential subjects can be screened and consented the day of their stroke (Day 1). Treatment with umbilical cord blood (UCB) cells or placebo will be administered intravenously as a single infusion as early as 3 days but no later than 10 days after the patient's stroke. UCB units will be selected from an accredited U.S. public cord bank based on blood type, race and a targeted cell dose ranging between 0.5 to 5 x 10^7 total nucleated cell count (TNCC)/kg. Study subjects will not receive immunosuppressive or myeloablative medications prior to infusion of the cord blood or placebo.

All subjects, families and medical staff will be blinded to treatment arm. When a subject is randomized to study drug at a clinical site without a cord blood bank, the selected cord blood units (CBU) will be shipped frozen overnight to the site. Once selected and available on site, each CBU will be thawed, washed, tested, released and infused intravenously using common standard operating procedures (SOPs) at all sites. For subjects randomized to placebo, a diluent with the same appearance and odor as a CBU will be prepared.

Patients will have baseline magnetic resonance imaging (MRI) and will be assessed at 1, 3, 6, and 12 months for functional outcomes. All patients will receive standard of care therapy while enrolled in this study and all subjects will be strongly encouraged to participate in rehabilitative therapy.

The primary objective of the study is to determine, in a randomized, placebo controlled trial, the efficacy of a single intravenous (IV) infusion of unrelated donor UCB for improving functional outcomes in patients with ischemic stroke. The secondary objectives are as follows:

  1. To describe the safety and tolerability of a single IV infusion of unrelated donor UCB in patients with ischemic stroke

  2. To evaluate the efficacy of a single IV infusion of unrelated donor UCB for improvement of neurological symptoms following ischemic stroke

  3. To evaluate the efficacy of a single IV infusion of unrelated donor UCB for improvement in quality of life and emotional and cognitive status in patients with ischemic stroke

Study Design

Study Type:
Interventional
Actual Enrollment :
83 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Triple (Participant, Care Provider, Investigator)
Primary Purpose:
Treatment
Official Title:
Phase 2 Study of Allogeneic Umbilical Cord Blood Infusion for Adults With Ischemic Stroke - CoBIS 2
Actual Study Start Date :
Mar 14, 2017
Actual Primary Completion Date :
Jul 17, 2020
Actual Study Completion Date :
Mar 27, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: Umbilical Cord Blood

A single intravenous infusion of umbilical cord blood within 3-10 days following stroke.

Biological: Umbilical Cord Blood
Umbilical cord blood will be infused intravenously through a peripheral IV line after premedication with diphenhydramine, hydrocortisone, and acetaminophen. Units will be from a public cord blood bank with selection based on blood type, race, and the number of cells in the pre cryopreservation product, targeting a dose range of 0.5 to 5 x 10^7 TNCC/kg.
Other Names:
  • cord blood
  • hematopoietic stem cells
  • Placebo Comparator: Placebo

    A single intravenous infusion of diluent with the same appearance and odor as a cord blood unit within 3-10 days following stroke.

    Other: Placebo
    The placebo product will be acellular and will consist of tissue culture medium 199 (TC-199 [pink]) with 1% dimethyl sulfoxide (DMSO), which are standard components in cellular products. The volume of placebo product will be 50 mL, which is in the range of a typical UCB unit that has been washed and thawed after cryopreservation. Infusion and premedication procedures will be the same as those conducted for the umbilical cord blood arm.

    Outcome Measures

    Primary Outcome Measures

    1. Shift in modified Rankin Scale (mRS) [3 months post infusion]

      shift in modified Rankin Scale (mRS) from baseline to 3 months post infusion.

    Secondary Outcome Measures

    1. Incidence and severity of infusion reactions [1 year post infusion]

      Incidence and severity of infusion reactions

    2. Incidence and severity of product-related infections [1 year post infusion]

      Incidence and severity of product-related infections

    3. Incidence of alloimmunization [1 year post infusion]

      Incidence of alloimmunization

    4. Incidence and severity of graft vs. host disease [1 year post infusion]

      Incidence and severity of graft vs. host disease

    5. Incidence and severity of study related and unexpected Adverse Events (AEs) [1 year post infusion]

      Incidence and severity of study related and unexpected AEs

    6. Mortality [1 year post infusion]

      Mortality

    7. Functional independence [90 days post infusion]

      Functional independence at 90 days defined as a 90-day mRS score of 0, 1, or 2

    8. mRS shift [30 days post infusion]

      shift in mRS score between baseline and day 30

    9. mRS shift [180 days post infusion]

      shift in mRS score between baseline and day 180

    10. NIHSS [90 days post infusion]

      The National Institutes of Health Stroke Scale (NIHSS) score at 90 days

    11. Barthel Index [90 days post infusion]

      The Barthel Index (BI) score at 90 days

    12. Stroke Impact Scale [90 days post infusion]

      Stroke Impact Scale-16 (SIS-16) score at 90 days

    13. European Quality of Life [90 days post infusion]

      The European Quality of Life (EQ-5D-3L) survey score at 90 days

    14. Patient Health Questionnaire Scale [90 days post infusion]

      Patient Health Questionnaire Scale (PHQ 8) score at 90 days

    15. Telephone Interview for Cognitive Status [30 days post infusion]

      Telephone Interview for Cognitive Status (TICS) total score at 30 days post infusion

    16. Telephone Interview for Cognitive Status [1 year post infusion]

      Telephone Interview for Cognitive Status (TICS) total score at 1 year post infusion

    17. Trail Making Test [90 days post infusion]

      Trail Making Test score at 90 days post infusion

    18. Montreal cognitive Assessment (MoCA) [90 days post infusion]

      Montreal cognitive Assessment score at 90 days post infusion

    19. Hopkins Verbal Learning Test-Revised (HVLT-R) [90 days post infusion]

      Hopkins Verbal Learning Test-Revised score at 90 days post infusion

    20. Patient Health Questionnaire (PHQ-8) [6 months post infusion]

      Patient Health Questionnaire score at six months post infusion

    21. Short Form 36 Health Survey (SF-36) [90 days post infusion]

      Short Form 36 Health Survey score at 90 days post infusion

    22. Controlled Oral Word Association test (COWAT) [90 days post infusion]

      Controlled Oral Word Association Test score at 90 days post infusion

    23. Oral Symbol Digit Modalities Test (SDMT) [90 days post infusion]

      Oral Symbol Digit Modalities Test score at 90 days post infusion

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    18 Years to 90 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    No
    Inclusion Criteria:
    1. 18-90 years old

    2. Recent, acute, cortical, hemispheric, ischemic stroke in the MCA distribution without a clinically significant midline shift as detected by MRI as a DWI abnormality. If unable to obtain a MRI scan, patients may be included if there is clear evidence of ischemic cortical involvement in the MCA distribution demonstrated by computed tomography and a clinical exam consistent with cortical involvement.

    3. NIHSS 6-15(R) and 6-20 (L) at the time of informed consent. Subjects with a >4-point increase of NIHSS from time of consent (worsening of score) will not be eligible for infusion.

    4. Subjects must have a platelet count >100,000/uL, hemoglobin >8gm/dL, absolute lymphocyte count (ALC) ≥ 1200 for African American patients and ≥1500 for all other racial-ethnic groups, and WBC >2,500/uL OR Historical pre-stroke value of ALC ≥ 1200 for African American and ≥1500 for all other racial-ethnic groups within 6 months of stroke

    -And- a post stroke ALC value of ≥ 1000, platelet count >100,000/uL, hemoglobin

    8gm/dL and WBC >2,500/uL.

    1. Subjects who received tPA or underwent endovascular reperfusion may be included in the study

    2. Able to provide consent to study or consent is obtained from the patient's legal representative

    3. Subjects of childbearing potential must practice effective contraception during the study, and be willing to continue contraception for at least 6 months after intervention so that, in the opinion of the Investigator, they will not become pregnant during the course of the study

    4. Is a good candidate for the trial, in the opinion of the Investigator

    5. Agrees to participate in follow-up visits

    6. ABO/Rh and race matched CBU(s) with a minimum of 0.5 x 10^7 TNCC/kg based on the pre-cryopreservation TNCC is available for infusion

    7. Has not had a disease or therapy that would compromise current immune function.

    8. Has a serum creatinine ≤2 mg/dL OR Glomerular Filtration Rate (GFR) ≥30mL/min

    Exclusion Criteria:
    An individual is ineligible to participate if any of the following apply:
    Exclusionary Medical Conditions:
    1. Medical history of neurological or orthopedic pathology with a deficit as a consequence that results in a modified Rankin Scale >1 before stroke or has a pre existing cognitive deficit

    2. Clinically significant and/or symptomatic hemorrhage associated with stroke

    3. Evidence of significant midline shift as assessed by CT or MRI who are felt to be at high risk for neurological decompensation or need for decompressive hemicraniectomy due to hemispheric edema

    4. New intracranial hemorrhage, edema, or mass effect that may place patient at increased risk for secondary deterioration when assessed prior to infusion

    5. Hypotension as defined as the need for IV pressor support of SBP <90

    6. Isolated brain stem stroke

    7. Pure lacunar stroke

    8. At time of consent, patients who are mechanically ventilated or, at the investigator's discretion are felt to be likely to need mechanical ventilation are excluded.

    9. Requires a craniotomy

    10. Serious psychiatric or neurological disease which could alter evaluation on functional or cognitive scales

    11. Active systemic infection that is felt, at the discretion of the Investigator, to place the patient at increased risk for participation in this study

    12. Documentation of human immunodeficiency virus positive (HIV+) status in the medical record

    13. Active malignancy within 3 years prior to the start of screening excluding skin cancers other than melanoma

    14. Known hypercoagulable state or coagulopathy deficiencies such as Factor V Leiden, Antiphospholipid Syndrome (APC), Protein C, Protein S, anticardiolipin antibody, phospholipid syndrome or Sickle Cell Disease

    15. History of or currently active autoimmune disease, or current immunomodulatory therapy or a recipient of immunomodulatory therapy in the past year.

    16. Concurrent illness or condition that in the opinion of the Investigator might interfere with treatment or evaluation of safety

    17. Current or recent history of alcohol or drug abuse, or stroke associated with drug abuse that Investigator feels may impair therapy or assessments

    18. Pregnant as documented by blood test

    Prohibited Concomitant or Prior Therapies

    1. Patients currently receiving immunosuppressant drugs, not including glucocorticoid taper, topical/inhaled glucocorticoids

    2. History of prior transfusion reaction

    3. Currently on dialysis

    4. Recipient of bone marrow or organ transplant

    5. Hepatic insufficiency (bilirubin >2.5mg/dL or transaminases >5x the ULN) Patients with Gilberts syndrome are eligible for study enrollment if other liver function tests are normal, regardless of bilirubin level

    6. Previous or current treatment with angiogenic growth factors, cytokines, gene or stem cell therapy

    7. Participating in another interventional clinical trial of an investigational therapy within 30 days of consent.

    Other Exclusion Criteria

    1. Pregnant or lactating women

    2. Unable or unwilling to be evaluated for follow-up visits

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 University of Colorado Anschutz Medical Campus Aurora Colorado United States 80045
    2 University of Florida Health Shands Hospital Gainesville Florida United States 32610
    3 Emory University School of Medicine Atlanta Georgia United States 30303
    4 Duke University Medical Center Durham North Carolina United States 27710
    5 Wake Forest Baptist Medical Center Winston-Salem North Carolina United States 27157
    6 Houston Methodist Houston Texas United States 77030

    Sponsors and Collaborators

    • Joanne Kurtzberg, MD
    • The Marcus Foundation
    • Emory University
    • M.D. Anderson Cancer Center

    Investigators

    • Principal Investigator: Joanne Kurtzberg, MD, Duke University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Joanne Kurtzberg, MD, Director, Robertson Clinical and Translational Cell Therapy Program, Duke University
    ClinicalTrials.gov Identifier:
    NCT03004976
    Other Study ID Numbers:
    • Pro00077580
    First Posted:
    Dec 29, 2016
    Last Update Posted:
    Aug 20, 2021
    Last Verified:
    Aug 1, 2021
    Individual Participant Data (IPD) Sharing Statement:
    No
    Plan to Share IPD:
    No
    Studies a U.S. FDA-regulated Drug Product:
    Yes
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Joanne Kurtzberg, MD, Director, Robertson Clinical and Translational Cell Therapy Program, Duke University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Aug 20, 2021